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Abstract
AIM: To evaluate the prognosis of type Ⅱ diabetes 
mellitus (T2DM) after gastrectomy and related factors 
in gastric cancer patients.
METHODS: 403 gastric cancer patients with T2DM 
were studied, who underwent gastrectomy between 
May 2003 and September 2009. A review of medical 
records and telephone interviews was performed in this 
cross-sectional study. The factors included in the statis-
tical analysis were as follows: gender, age, type of sur-
gery, preoperative body mass index (BMI), current BMI, 
BMI reduction ratio, preoperative insulin or oral diabetic 
medicine requirement, follow-up duration, and current 
state of diabetes. Assessment of diabetes status after 
surgery was classified into four categories according 
to the change in hypoglycemic agents after surgery 
and present status of T2DM: resolution, improvement, 
same, and worse. 
RESULTS: The mean follow-up duration was 33.7 mo 
(± 20.6 mo), preoperative BMI was 24.7 kg/m2 (± 3.0 
kg/m2), and BMI reduction ratio was 9.8% (± 8.6%). 
After surgery, T2DM was cured in 58 patients (15.1%) 
and was improved in 117 patients (30.4%). According 
to the type of surgery, the BMI reduction ratio was sig-
nificantly higher in the total gastrectomy and Roux-en-Y 
reconstruction group [14.2% ± 9.2% vs  9.2% ± 7.7% 
(Billroth Ⅱ group), P  < 0.001] and significantly lower in 
the subtotal gastrectomy and Billroth Ⅰ reconstruction 
group [7.6% ± 8.0%, 9.2% ± 7.7% (Billroth Ⅱ group), 
P  < 0.001]. The BMI reduction ratio, follow-up duration 
after surgery, type of surgery, extent of gastrectomy, 
and performance of duodenal bypass were significantly 
correlated to the course of T2DM (P  < 0.05). The BMI 
reduction ratio was the most influential factor on T2DM 
status. In a subgroup analysis of patients with a BMI 
reduction ratio of 10% or less (n  = 206), T2DM was 
cured in 15 (7.6%) patients and was improved in 57 
(28.8%) patients after surgery, and only the duration 
of surgery was significantly correlated to T2DM status (P 
= 0.022).
CONCLUSION: The course of T2DM was significantly 
correlated to the BMI reduction ratio but not to the 
type of surgery without a significant change in BMI. 
© 2012 Baishideng. All rights reserved.
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Table 1  Clinical findings [n  = 403, n  (%) or mean ± SD]INTRODUCTION
Gastrointestinal surgery has been established as the treat-
ment of  choice for patients with inadequately controlled 
type 2 diabetes mellitus (T2DM) and a body mass index 
(BMI) greater than or equal to 35 kg/m2[1]. However, in-
dications for bariatric surgery in the treatment of  T2DM 
are not clear. T2DM is improved by calorie restriction 
and weight loss, which can be aided by bariatric surgery.
Recently, it was reported that bariatric surgery to treat 
morbid obesity along with T2DM resulted in ameliora-
tion of  T2DM, including weight loss[2-6]. In addition, a 
non-randomized, comparative Swedish Obesity Study 
showed that regaining weight led to recurrence of  dia-
betes through long-term follow-up[7]. However, bariatric 
surgery may improve glycemic control in T2DM within 
days, even before considerable weight loss occurs. The 
exact mechanism for the dramatic effect of  obesity sur-
gery on T2DM remains unknown. T2DM has been ap-
proached from a new angle as an intestinal disease, which 
is increasingly viewed as operable[8-11].
These findings prompted clinicians to extend indica-
tions for bariatric surgery to non-obese patients with 
T2DM. In the 1950s and 60s, amelioration of  diabetes 
following subtotal gastrectomy was reported[12,13]. Since 
then, there have been few reports with inconsistent re-
sults in this area[14,15]. 
In this study, we compared the effects of  gastrointes-
tinal, anatomical rearrangements on diabetes after surgery 
for gastric cancer.
MATERIALS AND METHODS
Between May 2003 and September 2009, 6848 patients 
with gastric cancer underwent gastrectomy at Severance 
Hospital and Gangnam Severance Hospital, the Yonsei 
University College of  Medicine. Of  these patients, 576 
had diabetes; the diagnosis of  diabetes was based on the 
criteria of  the American Diabetes Association and the 
World Health Organization. We excluded 81 patients who 
expired or had cancer recurrence and 92 patients who 
could not be surveyed, leaving 403 patients to be enrolled 
for this study. To exclude type 1 diabetes, we reviewed 
patient medical records and interviewed these individuals 
about their type and history of  diabetes, but no patients 
were diagnosed with or suspected to have type 1 diabetes. 
Data were collected by a review of  medical records and 
interviews via telephone. The following factors were sta-
tistically analyzed: gender, age, type of  surgery, preopera-
tive BMI, current BMI, BMI reduction ratio, preoperative 
insulin or oral diabetic medicine requirement, follow-up 
duration, and current state of  diabetes. “Resolution” was 
defined as a case where the patient became euglycemic 
or an HbA1c level was maintained below 6% without the 
use of  diabetes medication after surgery. “Improvement” 
was defined as a case where the patient showed a bet-
ter fasting glucose level and either used a lower dose of  
hypoglycemic agents or converted to oral hypoglycemic 
agents from insulin, compared with preoperative diabetic 
control. “Same” or “worse” was defined as a case in 
which no change occurred (“same”) or an aggravation in 
fasting glucose and medication after surgery (“worse”) 
was observed. Patients were divided into three groups 
by type of  surgery: gastroduodenostomy after subtotal 
gastrectomy [Billroth Ⅰ (B-Ⅰ) group], gastrojejunostomy 
after subtotal gastrectomy [Billroth Ⅱ (B-Ⅱ) group], and 
Roux-en-Y esophagojejunostomy after total gastrectomy 
(R-Y group). 
SPSS version 12.0 for Windows (SPSS Inc., Chicago, 
IL, United States) was used for all statistical analyses. All 
data were analyzed using the paired sample t test, analysis 
of  variance, and ordinal logistic regression analysis. A P 
value of  less than 0.05 was considered significant. 
This study was approved by the Institutional Review 
Board of  Gangnam Severance Hospital (approval num-
ber 3-2020-0259).
RESULTS
The characteristics of  the subjects are summarized in 
Table 1. Of  403 patients, 58 patients (15.1%) were eu-
glycemic without medication, and 117 patients (30.4%) 
showed improved metabolic conditions but were still 
taking medication. In contrast, 172 patients (44.7%) did 
not change their medication for diabetes, and 38 patients 
(9.9%) had aggravated conditions (Table 1). 
Univariate analyses were carried out to determine the 
impact of  factors contributing to the amelioration of  
diabetes. The course of  diabetes after surgery was signifi-
cantly different between the R-Y and B-Ⅰ groups (P = 
0.001) and between the R-Y and B-Ⅱ groups (P = 0.006), 
but not between the B-Ⅰ and B-Ⅱ groups (P = 0.161). 
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Gender Female   96 (23.8)
Male 307 (76.2)
Age at OP (yr)   63.8 ± 7.6
OP type B-Ⅰ 165 (40.9)
B-Ⅱ 134 (33.3)
R-Y 104 (25.8)
Extent of gastrectomy Subtotal (B-Ⅰ, B-Ⅱ) 299 (74.2)
Total (R-Y) 104 (25.8)
Duodenal bypass Bypass – (B-Ⅰ) 165 (40.9)
Bypass + (B-Ⅱ, R-Y) 238 (59.1)
Pre-OP BMI (kg/m2) 24.7 ± 3.0 (18.4-39.9)
Current BMI (kg/m2) 22.2 ± 2.9 (13.5-35.3)
BMI reduction ratio1 (%)     9.8 ± 8.6
Pre-OP Oral diabetic agent 368 (91.3)
diabetic therapy Insulin 35 (8.7)
F/U duration (mo) 33.7 ± 20.6 (5.5-81.8)
Diabetes course Worse 38 (9.9)
Same 172 (44.7)
Improvement 117 (30.4)
Resolution   58 (15.1)
1BMI reduction ratio (%) = -[(Current BMI - Pre-OP BMI)/Pre-OP BMI] × 
100. OP: Operation; BMI: Body mass index; F/U: Follow up; B-Ⅰ : Billroth 
Ⅰ; B-Ⅱ: Billroth Ⅱ; R-Y: Roux-en-Y. 
We categorized patients into two groups by the extent 
of  gastrectomy. Diabetes was significantly improved in 
the total gastrectomy group compared with the subtotal 
gastrectomy group (P < 0.001) All patients were then 
categorized into two groups by the presence of  duodenal 
bypass. Patients who received duodenal bypass had signifi-
cantly improved diabetes compared to those who did not 
(P = 0.002, Table 2). In addition, the course of  diabetes 
was significantly correlated with current BMI and BMI 
reduction ratio (P = 0.038 and P < 0.001, respectively). 
Diabetes was improved immediately after surgery, gradu-
ally worsening over a longer term (P = 0.001, Table 2).
Ordinal logistic regression analysis was performed 
to determine significant factors affecting the course of  
diabetes. Because surgery type, extent of  gastrectomy, 
and duodenal bypass were similar factors, when the 
three factors were entered simultaneously in multivariate 
analysis, all were insignificant. Therefore, we performed 
multivariate analysis three times according to the three 
types of  surgery. In all three multivariate analyses, the 
BMI reduction ratio and follow-up duration were signifi-
cantly related to amelioration of  diabetes, but current 
BMI was not. Moreover, the absolute value of  contri-
bution degree of  the BMI reduction ratio was greatest 
among significant factors, so the BMI reduction ratio 
was found to have the biggest impact on diabetic status 
after three multivariate analyses (Table 3). Performance 
of  B-Ⅰ versus R-Y was a significant factor, but perfor-
mance of  B-Ⅱ versus R-Y was not. We used the extent 
of  gastrectomy or duodenal bypass as a covariate, and 
these factors were also significant. 
Based on these results, we investigated the association 
between weight change and type of  surgery. There was a 
significant decrease in BMI in the R-Y group, compared 
with the B-Ⅰ and B-Ⅱ groups (Figure 1A). There was 
also a significant difference in the BMI reduction ratio 
between the B-Ⅰ and B-Ⅱ groups. The total gastrectomy 
group showed significant weight loss compared with the 
subtotal gastrectomy group (P < 0.001, Figure 1B), and 
duodenal bypass lost significantly more weight than the 
non-duodenal bypass group (P < 0.001, Figure 1C).
These results suggest that the main factor influenc-
ing diabetes improvement might be weight loss instead 
of  type of  surgery. Therefore, we performed subgroup 
analysis of  the patients whose BMI reduction ratio was 
less than 10% of  the preoperative level. The mean BMI 
reduction ratio was 3.4% (± 5.4%; Table 4). In univariate 
analysis, type of  surgery was not a significant factor for 
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aP = 0.161, B-Ⅰ vs B-Ⅱ. 1BMI reduction ratio (%) = -[(Current BMI - Pre-OP BMI)/Pre-OP BMI] × 100. OP: Operation; BMI: Body mass index; F/U: Follow 
up; B-Ⅰ : Billroth Ⅰ; B-Ⅱ: Billroth Ⅱ; R-Y: Roux-en-Y. 
Table 3  Multivariate analysis (n  = 403)
P value B-estimation SE Contribution 
degree
Current BMI (kg/m2)     0.454   0.028 0.037
BMI reduction ratio1 (%) < 0.001   0.051 0.013   3.948
F/U duration (mo)    0.007 -0.013 0.005 -2.703
OP type
   B-Ⅰ     0.006 -0.714 0.258 -2.770
   B-Ⅱ    0.070 -0.473 0.262
   R-Y
Current BMI (kg/m2)    0.478   0.026 0.037
BMI reduction ratio1 (%) < 0.001   0.052 0.013   4.031
F/U duration (mo)    0.006 -0.013 0.005 -2.727
Extent of gastrectomy
   Subtotal (B-Ⅰ, B-Ⅱ)    0.011 -0.597 0.234 -2.553
   Total (R-Y)
Current BMI (kg/m2)    0.657   0.016 0.037
BMI reduction ratio1(%) < 0.001   0.054 0.013   4.181
F/U duration (mo)    0.005 -0.013 0.005 -2.811
Duodenal bypass
   Bypass – (B-Ⅰ)    0.039 -0.416 0.202 -2.061
   Bypass + (B-Ⅱ, R-Y)
OP: Operation; BMI: Body mass index; F/U: Follow up; B-Ⅰ : Billroth Ⅰ; B-
Ⅱ: Billroth Ⅱ; R-Y: Roux-en-Y; 1BMI reduction ratio (%) = -[(Current BMI - 
Pre-OP BMI)/Pre-OP BMI] × 100.
Table 2  Univariate analysis [n  = 403, n  (%) or mean ± SD]
Diabetes course P  value
Worse Same Improvement Resolution
Gender Female   8 (8.6)   36 (38.7) 34 (36.6) 15 (16.1)    0.180
Male   30 (10.3) 136 (46.6) 83 (28.4) 43 (14.7)
Age at OP (yr) 62.6 ± 7.6 64.2 ± 7.4 63.5 ± 7.4 62.5 ± 8.4    0.453
OP type B-Ⅰa   20 (12.4)   82 (50.9) 42 (26.1) 17 (10.6)    0.001
B-Ⅱa 10 (8.0)   59 (47.2) 42 (33.6) 14 (11.2)    0.006
R-Y   8 (8.1)   31 (31.3) 33 (33.3) 27 (27.3)
Extent of gastrectomy B-Ⅰ and B-Ⅱ (subtotal)   30 (10.5) 141 (49.3) 84 (29.4) 31 (10.8) < 0.001
 R-Y (total)   8 (8.1)   31 (31.3) 33 (33.3) 27 (27.3)
Duodenal bypass B-Ⅰ (bypass -)   20 (12.4)   82 (50.9) 42 (26.1) 17 (10.6)    0.002
B-Ⅱ and R-Y (bypass +) 18 (8.0)   90 (40.2) 75 (33.5) 41 (18.3)
Pre-OP BMI (kg/m2) 23.4 ± 2.5 24.9 ± 2.6 24.8 ± 3.5 24.9 ± 3.5    0.127
Current BMI (kg/m2) 21.7 ± 2.7 22.7 ± 2.6 22.2 ± 3.2 21.2 ± 2.9    0.038
BMI reduction ratio1 (%)     6.8 ± 10.2   8.5 ± 7.3 10.4 ± 8.7 14.4 ± 8.5 < 0.001
Pre-OP diabetic Oral diabetic agent   38 (10.8) 159 (45.3) 99 (28.2) 55 (15.7)    0.147
regimen Insulin   0 (0.0)   13 (38.2) 18 (52.9) 3 (8.8)
F/U duration (mo)   36.4 ± 18.2   37.2 ± 21.6   30.0 ± 20.1   28.3 ± 17.8    0.001
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1 diabetes. There were no patients who were diagnosed 
with or suspected to have type 1 diabetes. Furthermore, 
in Korea, the incidence of  type 1 diabetes is very low, 
reported as approximately 0.6-2.2/100  000[16-18]. Consid-
ering that type 1 diabetes is extremely rare in Korea and 
the mean age of  the study population was 63.8 years, the 
results of  this study showing that there were no cases of  
type 1 diabetes in 6848 patients of  the study population 
can be thought acceptable.
Possible mechanisms through which metabolic sur-
gery has led to the resolution of  T2DM are a decrease in 
calorie intake, weight loss, and a rearranged gastrointes-
tinal track, which could modulate hormones that affect 
glucose metabolism, insulin sensitivity, and beta pancre-
atic cell proliferation[19]. Several reports support a positive 
role for duodenojejunal exclusion and/or duodenal by-
pass for T2DM resolution after bariatric surgery in obese 
patients[20].
However, it is still unclear whether these effects extend 
to non-obese patients. One report stressed that gastrec-
tomy and short Roux-en Y reconstruction in non-obese 
T2DM patients correlate with remission of  diabetes in 
65% of  patients[14]. In that study, the preoperative BMI 
was 29.1 and the postoperative BMI was 24.6 kg/m2; such 
significant weight loss might explain the relatively high 
rate of  T2DM resolution after gastrectomy. Another study 
reported a resolution rate of  38.1% after gastrectomy 
with Roux-en Y gastrojejunostomy, which is similar to our 
results[15]. Early delivery of  partially digested foods to the 
ileum and discrete enteroendocrine cells in the mucosa are 
suggested to release hormones that contribute to the ileal 
brake[21]. However, we could not evaluate this point due to 
procedural limitations.
the amelioration of  diabetes (Table 5). However, in this 
subgroup of  203 patients, diabetes was resolved without 
medication in 15 patients (7.6%), and 57 patients (36.4%) 
improved without significant weight loss. 
DISCUSSION
This study was conducted in a retrospective manner. There-
fore, the type of  diabetes was not evaluated by laboratory 
testing but by reviewing medical records and interview-
ing. We interviewed all of  the enrolled patients and asked 
about the type and history of  diabetes to exclude type 
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Figure 1  Body mass index reduction ratio according to A: Type of sur-
gery; B: Extent of gastrectomy; C: Performance of duodenum bypass (n = 
403, mean ± SD). BMI: Body mass index; B-Ⅰ: Billroth Ⅰ; B-Ⅱ: Billroth Ⅱ; R-Y: 
Roux-en-Y.
Table 4  Clinical findings in subgroup analysis [body mass index 
reduction ratio < 10%, n = 206, n  (%) or mean ± SD]
Gender Female     38 (18.4)
Male   168 (81.6)
Age at OP (yr)
OP type B-Ⅰ   105 (51.0)
B-Ⅱ     68 (33.0)
R-Y     33 (16.0)
Extent of gastrectomy Subtotal (B-Ⅰ, B-Ⅱ)   173 (84.0) 
Total (R-Y)     33 (16.0) 
Duodenal bypass Bypass – (B-Ⅰ)   105 (51.0)
Bypass + (B-Ⅱ, R-Y)   101 (49.0)
Pre-OP BMI (kg/m2) 23.8 ± 2.8 (18.4-32.6) 
Current BMI (kg/m2) 23.0 ± 2.7 (21.8-32.5) 
BMI reduction ratio1 (%)       3.4 ± 5.4
Pre-OP diabetic regimen Oral diabetic agent   186 (90.3)
Insulin   20 (9.7)
F/U duration (mo)   35.7 ± 20.7 (5.5-81.1)
Diabetes course Worse     24 (12.1)
Same   102 (51.5)
Improvement     57 (28.8)
Resolution   15 (7.6)
OP: Operation; BMI: Body mass index; F/U: Follow up; B-Ⅰ : Billroth Ⅰ; B-
Ⅱ: Billroth Ⅱ; R-Y: Roux-en-Y; 1BMI reduction ratio (%) = -[(Current BMI - 
Pre-OP BMI)/Pre-OP BMI] × 100.
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One of  the mainstream T2DM treatments is reduc-
tion of  calorie intake; restrictive bariatric surgery effec-
tively controls T2DM in obese patients[2]. In this study, 
univariate and multivariate analyses showed that duodenal 
bypass and/or duodenojejunal exclusion groups dem-
onstrated a high rate of  T2DM resolution compared to 
other procedures. However, for patients who lost less 
than 10% of  their preoperative weight, the type of  sur-
gery was not significantly important for T2DM resolu-
tion. These results suggest that the usual procedures after 
gastrectomy for gastric cancer are ineffective to control 
T2DM directly. In addition, most gastrectomized patients 
for gastric cancer are not pathologically obese, and recon-
struction should not induce severe weight loss. 
Interestingly, diabetes worsened after improvements 
were observed for a short time after surgery. The limi-
tation of  this study, which is retrospective and cross-
sectional analysis, should be considered. Moreover, most 
gastric cancer patients are cautious about maintaining 
their weight for good nutrition. Therefore, it is possible 
that weight loss immediately after surgery improves 
T2DM, and as the patient regains weight, the condition 
deteriorates. In meta-analysis, the proportion of  patients 
with resolution or improvement was not significantly dif-
ferent at time points less than 2 years or 2 years or more 
after surgery, although it slightly decreased over time[2]. 
Several studies demonstrated that T2DM could be re-
solved after metabolic surgery, irrespective of  weight loss, 
via a modification in the enteroinsular axis[2,20,21]. Based on 
these findings, we tried to establish a new procedure for 
the resolution of  T2DM in non-obese patients. Unfortu-
nately, routine reconstruction surgery after gastrectomy 
could not control diabetes in non-obese patients, and the 
main mechanism for gastrectomy-induced resolution of  
T2DM is possibly weight loss, instead of  the type of  sur-
gery itself. Thus, a more sophisticated procedure should 
be developed and prospectively evaluated for its effective-
ness in controlling T2DM in gastric cancer patients after 
gastrectomy.
COMMENTS
Background
It has been frequently reported that bariatric surgery for morbid obesity along 
with type Ⅱ diabetes mellitus (T2DM) results in amelioration of T2DM, includ-
ing weight loss. Furthermore, in some reports, bariatric surgery may improve 
glycemic control in T2DM within days, even before considerable weight loss 
occurs. These findings prompted clinicians to consider T2DM as an operable 
gastrointestinal disease and extend indications for bariatric surgery to non-
obese patients with T2DM. However, the application of surgery for non-obese 
T2DM patients has considerable risks. In Korea,  many cases of gastric cancer 
have been performed by gastric cancer surgery. In this study, the effects of 
gastrointestinal, anatomical rearrangements on diabetes were compared after 
surgery for gastric cancer.
Research frontiers
This is a retrospective but very large-scale study. The authors interviewed all of 
the enrolled subjects via telephone.
Innovations and breakthroughs
In the 1950s and 60s, amelioration of diabetes following subtotal gastrectomy 
was reported. Since then, there have been few reports in this area with incon-
sistent results. In those reports, the numbers of cases were very small. In this 
study, 403 patients were enrolled, and we evaluated the factors affecting the 
course of diabetes. The authors demonstrated that 15% of T2DM was cured 
after gastrectomy with conventional reconstruction. The extent of gastrectomy, 
type of reconstruction, and change in body mass index (BMI) were related to 
the course of diabetes. Among these factors, the change in BMI was the stron-
gest. In the subgroup analysis of small BMI changes, the extent of gastrectomy 
and the type of reconstruction were not statistically related to the course of 
diabetes, which did not support the foregut hypothesis. 
Applications
The results of this study can be used as reference data for further study. In oth-
er words, in some study of innovative treatment for diabetes in gastric cancer 
patients, the results could be used for the calculation of the number of subjects 
required and provide reference data for comparison. In addition, duodenal by-
pass itself is not a critical factor in metabolic surgery.
Terminology
The term duodenal bypass means a condition in which ingested food material 
aP = 0.674, B-Ⅰ vs B-Ⅱ; OP: Operation; BMI: Body mass index; F/U: Follow up; B-Ⅰ : Billroth Ⅰ; B-Ⅱ: Billroth Ⅱ; R-Y: Roux-en-Y; 1BMI reduction ratio (%) = 
-[(Current BMI - Pre-OP BMI)/Pre-OP BMI] × 100.
Table 5  Subgroup analysis [body mass index reduction ratio < 10%, n  = 206, n  (%) or mean ± SD]
Diabetes course P  value
Worse Same Improvement Remission
Gender Female 3 (8.1) 17 (45.9) 14 (37.8)   3 (8.1) 0.190
Male 21 (13.0) 85 (52.8) 43 (26.7) 12 (7.5)
Age at OP (yr) 61.9 ± 8.1 63.9 ± 8.0 63.8 ± 7.5 61.1 ± 9.3 0.976
OP type B-Ⅰa 14 (13.5) 56 (53.8) 27 (26.0)   7 (6.7) 0.076
B-Ⅱa   7 (11.3) 33 (53.2) 18 (29.0)   4 (6.5) 0.181
R-Y 3 (9.4) 13 (40.6) 12 (37.5)     4 (12.5)
Extent of gastrectomy Subtotal (B-Ⅰ, B-Ⅱ) 21 (12.7) 89 (53.6) 45 (27.1) 11 (6.6) 0.084
Total (R-Y) 3 (9.4) 13 (40.6) 12 (37.5)     4 (12.5)
Duodenal bypass Bypass – (B-Ⅰ) 14 (13.5) 56 (53.8) 27 (26.0)   7 (6.7) 0.250
Bypass + (B-Ⅱ, R-Y) 10 (10.6) 46 (48.9) 30 (31.9)   8 (8.5)
Pre-OP BMI (kg/m2) 22.7 ± 2.3 24.3 ± 2.7 23.8 ± 3.0 22.2 ± 2.8 0.615
Current BMI (kg/m2) 22.3 ± 2.2 23.4 ± 2.6 23.0 ± 3.1 21.3 ± 2.6 0.310
BMI reduction ratio1 (%)   1.5 ± 6.6   3.7 ± 4.5   3.6 ± 5.9   4.2 ± 4.6 0.183
Pre-OP Oral diabetic agent 24 (13.5) 93 (52.2) 47 (26.4) 14 (7.9) 0.080
diabetic
regimen Insulin 0 (0.0)   9 (45.0) 10 (50.0)   1 (5.0)
F/U duration (mo)  37.7 ± 17.6   38.8 ± 21.7   30.7 ± 20.7   28.7 ± 14.1 0.022
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does not traverse the duodenum. In both Billroth Ⅱ reconstruction after subto-
tal gastrectomy and Roux-en-Y reconstruction after total gastrectomy, ingested 
food materials go directly to the jejunum. Metabolic surgery is a field of sur-
gery that attempts to treat metabolic syndrome, including diabetes. Hormonal 
changes after metabolic surgery are thought to be important. Both the hindgut 
hypothesis (the quick transit of nutrients to the distal bowel is important) and 
the foregut hypothesis (the exclusion of the proximal small intestine induces 
resolution of T2DM) have been proposed. 
Peer review
This paper summarized the effect of gastrectomy on T2DM in a large number of 
patients.
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